Based on in vivo mice experiments using human serum albumin-conjugated soluble EphB4, it was confirmed that EphB4 could serve as a potential therapeutic target in pancreatic ductal adenocarcinoma and further research is necessary to prove its efficacy in the treatment of pancreatic cancer patients. The gene discussed is EPHB4; the disease is familial pancreatic carcinoma.